SCHEMBL5553396

SCHEMBL5553396

O=C(c1cc(C(F)(F)F)cc(C(F)(F)F)c1)N1CCC2(CC1)C(=O)NCC2c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 9/20 0.56
CYP3A4 P08684 3/20 0.54
TSHR P16473 2/20 0.54
USP2 O75604 5/20 0.53
HSD17B10 Q99714 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.50
CYP2C9 P11712 2/20 0.50
HIF1A Q16665 2/20 0.49
ALDH1A1 P00352 1/20 0.49
CYP2D6 P10635 1/20 0.49
HPGD P15428 1/20 0.49
ALOX15 P16050 1/20 0.49
MAPK1 P28482 1/20 0.49
OPRM1 P35372 5/20 0.48
SLC6A5 Q9Y345 3/20 0.48
OPRL1 P41146 1/20 0.48
KCNH2 Q12809 1/20 0.48
TACR1 P25103 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5553243 0.86 CYP3A4 (0.48) CYP3A4TSHRUSP2HSD17B10SMN1; SMN2
SCHEMBL5012152 0.84 CYP3A4 (0.53) CYP3A4TSHRUSP2HSD17B10SMN1; SMN2
SCHEMBL5010920 0.84 CYP3A4 (0.53) CYP3A4TSHRUSP2HSD17B10SMN1; SMN2
SCHEMBL5553288 0.82 CYP3A4 (0.55) CYP3A4TSHRUSP2HSD17B10SMN1; SMN2
SCHEMBL7147194 0.80 USP2 (0.55) CYP3A4TSHRUSP2HSD17B10SMN1; SMN2
SCHEMBL5559655 0.76 CYP3A4 (0.53) CYP3A4TSHRUSP2HSD17B10SMN1; SMN2
SCHEMBL5559632 0.75 USP2 (0.51) CYP3A4TSHRUSP2HSD17B10SMN1; SMN2
SCHEMBL5558298 0.75 HIF1A (0.57) CYP3A4TSHRUSP2HSD17B10SMN1; SMN2
SCHEMBL5012057 0.75 CYP3A4 (0.52) CYP3A4TSHRUSP2HSD17B10SMN1; SMN2
SCHEMBL5012054 0.75 CYP3A4 (0.52) CYP3A4TSHRUSP2HSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6482829-B2 CENTRAL NERVOUS SYSTEM DISORDERS; HEEADACHES, ANTIINFLAMMATORY AGENTS HOFFMANN-LA ROCHE INC. 2002-11-19 US claimed
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor F. HOFFMANN-LA ROCHE AG (CH) 2002-01-17 US claimed
EP-1292596-B1 1,3,8-TRIAZA-SPIRO¬4,5 DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2007-12-19 EP disclosed
EP-1292596-A1 1,3,8-TRIAZA-SPIRO[4,5]DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-03-19 EP disclosed
US-6482829-B2 CENTRAL NERVOUS SYSTEM DISORDERS; HEEADACHES, ANTIINFLAMMATORY AGENTS HOFFMANN-LA ROCHE INC. 2002-11-19 US disclosed
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor F. HOFFMANN-LA ROCHE AG (CH) 2002-01-17 US disclosed
WO-2001094346-A1 1,3,8-TRIAZA-SPIRO'4,5!DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor TACR1, TACR2, NPR1 SLC6A9 2463/4885CYP3A4 3223/4885TSHR 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.